https://www.selleckchem.com/pr....oducts/Sapogenins-gl
gov ID NCT03507192, 24/04/2018). To determine the efficacy of a potassium-competitive acid blocker (P-CA-based first-line eradication therapy with bismuth compared with that of proton pump inhibitor-based first-line therapy with bismuth. Eradication-naive -infected patients were consecutively enrolled from January to November 2020. Before approval of the P-CAB-based eradication therapy, twice daily administration of a regimen containing lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and bismuth potassium cit
Like
Comment
Share
